Interest is growing in discussions by the Ministry of Health, Labor and Welfare’s (MHLW) new expert panel on comprehensive pharmaceutical measures. At its meeting on September 22, major trade groups made their cases to push for a re-think of the…
COMMENTARY
Delving into Potential Implications of Envisaged Price Revision Overhaul
Discussions are underway in and outside the pharmaceutical industry to explore a new NHI price revision method for listed medicines that could replace the current rules based on market prices. Parties like the Study Group on Drug Pricing and Distribution…
To read the full story
Related Article
COMMENTARY
- Pharma Industry Faces Hurdles in Getting Medical Circle to Accept Softer Drug Price Cut Plan
September 28, 2022
- Generic Industry Has High Hopes on New Expert Panel; Will Its Recommendations Ease Impact of Annual Re-Pricing?
September 9, 2022
- Tussle in Japan Diabetes Market Heating Up; BI and Sumitomo Nip and Tuck for No. 1 Slot
August 29, 2022
- Launch of New Expert Panel Nears, How Can It Make Its Proposal Productive?
August 25, 2022
- Pharma Eyes Riveted on JMA’s Stance on Off-Year Revision as New Chief Builds Ties with Govt
August 22, 2022
Healthcare in the US is a highly political topic, with one end of the political spectrum arguing for broader government-sponsored access and the other advocating for more of a free-market approach. While the US market has typically been the primary…
The average ratio of females in managerial posts at Japanese drug makers has finally reached a double-digit number, at 10.0%, a Jiho survey found. However, this is still well below a near-25% ratio logged by foreign players operating in the…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…
A total of 15 new drugs (APIs) joined the NHI price list in 2021 with peak sales forecasts topping at 10 billion yen, many of them in the area of orphan diseases and with few mega launches, according to a…